Annals of Coloproctology

Display

Sort by :

Original Articles

Malignant disease,Colorectal cancer

Upregulation of prostaglandin E₂ by inducible microsomal prostaglandin E synthase-1 in colon cancer: Young Hun Kim, Kyung Jong Kim; Ann Coloproctol. 2022;38(2):153-159. Published online August 31, 2021; DOI: https://doi.org/10.3393/ac.2021.00374.0053

4,759 View
157 Download
8 Web of Science
7 Citations

Purpose
Prostaglandin E₂ (PGE₂) is known to promote carcinogenesis and cancer progression in colon cancer. Enzymes involved in the metabolism of PGE₂ include cyclooxygenase (COX)-2, microsomal prostaglandin E synthase-1 (mPGES-1), and 15-prostaglandin dehydrogenase (15-PGDH). The current study aims to determine how PGE₂ is expressed by examining patients with colorectal cancer and evaluating colon cancer cells to gain insight into changes in relevant enzymes upon induction of PGE₂.
Methods
The concentration of PGE₂ was measured in tumor tissues and adjacent normal mucosal tissues of 26 patients with colon cancer. The expression of COX-1, COX-2, mPGES-1, and 15-PGDH proteins was measured. The concentration of PGE₂ in FET colon cancer cells was measured both in the initial status and after stimulation by tumor necrosis factor (TNF)-α. The expression levels of PGE₂-related enzymes were measured as well.
Results
There was no significant difference in the average concentration of PGE₂, which was measured at 453.1 pg/mL in cancer tissues and 401.2 pg/mL in normal mucosa. Among PGE₂-related enzymes, 15-PGDH was expressed at a lower level in tumor cells than in normal mucosa. In colon cancer cells, PGE₂ was found to be upregulated upon stimulation by TNF-α, which led to strong induction of mPGES-1 without any change in the expression of COX-2 among the PGE₂-related enzymes.
Conclusion
These results demonstrated that PGE₂ can be induced by stimuli such as TNF-α, and suggest that activation of mPGES-1 is more closely related than that of COX-2 in the induction of PGE₂ on colon cancer.

Citations

Citations to this article as recorded by

5‐methyl‐2‐carboxamidepyrrole‐based novel dual mPGES‐1/sEH inhibitors as promising anticancer candidates
Ester Colarusso, Gianluigi Lauro, Marianna Potenza, Paola Galatello, Maria Luisa d'Aulisio Garigliota, Maria Grazia Ferraro, Marialuisa Piccolo, Maria Giovanna Chini, Carlo Irace, Pietro Campiglia, Robert Klaus Hoffstetter, Oliver Werz, Anna Ramunno, Gius
Archiv der Pharmazie.2025;[Epub] CrossRef
Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition
Gianluigi Lauro, Michela Aliberti, Mauro De Nisco, Silvana Pedatella, Giacomo Pepe, Manuela Giovanna Basilicata, Maria Giovanna Chini, Katrin Fischer, Robert K. Hofstetter, Oliver Werz, Maria Grazia Ferraro, Marialuisa Piccolo, Carlo Irace, Anella Saviano
European Journal of Medicinal Chemistry.2025; 289: 117402. CrossRef
Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4
Ana Santiso, Akos Heinemann, Julia Kargl
Pharmacological Reviews.2024; 76(3): 388. CrossRef
The calcium-sensing receptor modulates the prostaglandin E2 pathway in intestinal inflammation
Valeriya Gushchina, Nadja Kupper, Michael Schwarzkopf, Gitta Frisch, Karina Piatek, Cornelia Aigner, Alexandra Michel, Hemma Schueffl, Luca Iamartino, Taha Elajnaf, Teresa Manhardt, Andrea Vlasaty, Petra Heffeter, Marcella Bassetto, Enikö Kállay, Martin S
Frontiers in Pharmacology.2023;[Epub] CrossRef
Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II–III Colorectal Cancer
Su Hyeong Park, Hye Seung Woo, In Kyung Hong, Eun Jung Park
Cancers.2023; 15(20): 5098. CrossRef
Prostaglandin E2 Exposure Disrupts E-Cadherin/Caveolin-1-Mediated Tumor Suppression to Favor Caveolin-1-Enhanced Migration, Invasion, and Metastasis in Melanoma Models
Lorena Lobos-González, Lorena Oróstica, Natalia Díaz-Valdivia, Victoria Rojas-Celis, America Campos, Eduardo Duran-Jara, Nicole Farfán, Lisette Leyton, Andrew F. G. Quest
International Journal of Molecular Sciences.2023; 24(23): 16947. CrossRef
Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis
Minsung Kim, Il Tae Son, Bo Young Oh
The Ewha Medical Journal.2023;[Epub] CrossRef

Prognostic Implication of 15-Hydroxyprostaglandin Dehydrogenase Down-Regulation in Patients with Colorectal Cancer: Pil Sung Kang, Jin Ha Kim, Ok In Moon, Sung Chul Lim, Kyung Jong Kim; J Korean Soc Coloproctol. 2012;28(5):253-258. Published online October 31, 2012; DOI: https://doi.org/10.3393/jksc.2012.28.5.253

4,643 View
50 Download
2 Citations

Abstract PDF

Purpose

Prostaglandin (PG) E2 is known to be closely related to cancer progression and is inactivated by 15-hydroxyprostaglandin dehydrogenase (PGDH). 15-PGDH is shown to have tumor suppressor activity and to be down-regulated in various cancers, including colorectal cancer (CRC). Therefore, we evaluated the expression of 15-PGDH and its prognostic effect in patients with CRC.

Methods

15-PGDH expression was examined by using immunohistochemistry in 77 patients with CRC. Its prognostic significance was statistically evaluated.

Results

Negative 15-PGDH expression was noted in 55.8% of the 77 cases of CRC. 15-PGDH expression showed no correlation with any of the various clinicopathologic parameters. The status of lymph node metastasis, tumor-node-metastasis stages, and pre-operative carcinoembryonic antigen levels showed significant prognostic effect. However, univariate analysis revealed down-regulation of 15-PGDH not to be a predictor of poor survival. The 5-year overall survival rate was 71.7% in the group with positive expression of 15-PGDH and 67.1% in the group with negative expression of 15-PGDH, but this difference was not statistically significant (P = 0.751).

Conclusion

15-PGDH was down-regulated in 55.8% of the colorectal cancer patients. However, down-regulation of 15-PGDH showed no prognostic value in patients with CRC. Further larger scale or prospective studies are needed to clarify the prognostic effect of 15-PGDH down-regulation in patients with colorectal cancer.

Citations

Citations to this article as recorded by

The tumor suppressor role and epigenetic regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in cancer and tumor microenvironment (TME)
SubbaRao V. Tulimilli, Medha Karnik, Anjali Devi S. Bettadapura, Olga A. Sukocheva, Edmund Tse, Gowthamarajan Kuppusamy, Suma M. Natraj, SubbaRao V. Madhunapantula
Pharmacology & Therapeutics.2025; 268: 108826. CrossRef
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
Nagendra S. Yarla, Venkateshwar Madka, Gopal Pathuri, Chinthalapally V. Rao
International Journal of Molecular Sciences.2020; 21(24): 9609. CrossRef

First
Prev
Page of 1
Next
Last

Search